Cambiar Investors’s BioTelemetry, Inc. BEAT Stock Holding History

Cambiar Investors’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-50,983	Closed	-$3.67M	–	168
2020 Q4	$3.67M	Sell	50,983 -1,360	-3%	-$71.2K	0.14%	91
2020 Q3	$2.39M	Buy	52,343 +14,723	+39%	+$615K	0.11%	99
2020 Q2	$1.7M	Sell	37,620 -12,534	-25%	-$562K	0.08%	133
2020 Q1	$1.93M	Sell	50,154 -1,725	-3%	-$79.4K	0.1%	92
2019 Q4	$2.4M	Sell	51,879 -2,126	-4%	-$92.1K	0.08%	104
2019 Q3	$2.2M	Buy	+54,005	New	+$2.33M	0.07%	122

Other funds holding BEAT

LCM

Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

Cambiar Investors's BEAT Position: Q1 2021 in Review

Cambiar Investors sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 50,983 shares — an estimated $3.67M sold.

Cambiar Investors first reported a position in BEAT in Q3 2019 and held it in 6 quarters. The position peaked at $3.67M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

Cambiar Investors reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
Cambiar Investors sold 50,983 BioTelemetry, Inc. shares in Q1 2021, an estimated $3.67M.
Cambiar Investors first reported a position in BioTelemetry, Inc. in Q3 2019 and held it in 6 quarters.
Cambiar Investors's BioTelemetry, Inc. position peaked at $3.67M in Q4 2020.
1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Cambiar Investors's 13F filing for Q1 2021, filed 14 May 2021.